![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » PharmaCyte’s Licensed SARS-CoV-2 Tests Earn CE Mark
PharmaCyte’s Licensed SARS-CoV-2 Tests Earn CE Mark
![PharmaCyteBiotech-logo.png](https://www.fdanews.com/ext/resources/test/Device_Images6/PharmaCyteBiotech-logo.png?t=1596148021&width=430)
PharmaCyte Biotech has earned a CE Mark certification for two COVID-19 polymerase chain reaction (PCR) tests and is launching them in Europe.
The Laguna Hills, California company licensed the two tests — a reverse transcription PCR test and an enhanced fluorescence real-time reverse transcription PCR test — from the Chinese company Hai Kang Life.
PharmaCyte said it plans to seek FDA authorization for a pool testing protocol that would allow multiple samples to be analyzed together.
Upcoming Events
-
21Oct